跳至主要内容
临床试验/NCT05525572
NCT05525572终止1 期

Combining Shockwave Therapy and Platelet Rich Plasma to Treat Erectile Dysfunction in Diabetic Men (COCKTAIL-DM)

University of Miami1 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2024年2月12日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
终止
入组人数
2
试验地点
1
主要终点
Markers of Vasodilation

研究概览

简要总结

The purpose of this research study is to evaluate whether the combination of Shockwave Therapy (SWT) with Platelet Rich Plasma (PRP) is synergistic and can reverse the pathology of microvascular Erectile Dysfunction (ED) and enhance erectile function in diabetics patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 80 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Between 30 to 80 years of age (inclusive).
  • Be able to provide written informed consent.
  • Have a diagnosis of Mild to Moderate ED (12-21) or Mild ED (22-25) based on International Index of Erectile Dysfunction - Erectile Function (IIEF-EF) questionnaire score.
  • Have diagnosis of Diabetes Mellitus (Type 1 or Type 2), as documented by history of Hemoglobin A1C > 7% OR on medical therapy for Diabetes.
  • Be in a stable relationship and have a minimum of 2 sexual attempts per month for at least one month prior to enrollment.
  • Agree to comply with all study related tests/procedures.

排除标准

  • Previous penile surgery of any kind (except circumcision and condyloma removal), such as penile lengthening, penile cancer surgery, penile plication, grafting.
  • Previous history of priapism, penile fracture, Peyronie's Disease, or penile curvature that negatively influences sexual activity.
  • Abnormal morning serum testosterone level defined as a value lower than 300 ng/dL (±5%).
  • Psychogenic ED as determined by study investigator.
  • Patients using Intracavernous Injections (ICI) for management of ED.
  • Patients with generalized polyneuropathy, neurological conditions, or psychiatric disease (such as bipolar disorder or depression).
  • Have a serious comorbid illness or condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.
  • History of consistent treatment failure with Phosphodiesterase 5 (PDE5) inhibitors for therapy of ED.
  • Poorly controlled diabetes as indicated by Hemoglobin a1c > 7.5%.
  • Use of antiplatelet medications

研究组 & 干预措施

Shockwave Therapy (SWT) + Platelet-Rich Plasma (PRP) Group

Experimental

Participants will receive a combination of 5 weekly extracorporeal shockwave therapy sessions (SWT) and two sessions of autologous platelet-rich plasma (PRP) penile injection.

干预措施: Shockwave Therapy (SWT) (Device)

Shockwave Therapy (SWT) + Platelet-Rich Plasma (PRP) Group

Experimental

Participants will receive a combination of 5 weekly extracorporeal shockwave therapy sessions (SWT) and two sessions of autologous platelet-rich plasma (PRP) penile injection.

干预措施: Autologous Platelet-Rich Plasma (PRP) (Drug)

结局指标

主要结局

Markers of Vasodilation

时间窗: Baseline, Month 3, Month 6

Markers of vasodilation including Endothelial Nitric Oxide Synthase (eNOS) and Neuronal Nitric Oxide Synthase (nNOS) will be measured from serum blood samples in units of ug/mL.

Endothelial Function Markers

时间窗: Baseline, Month 3, Month 6

Markers of endothelial function will include Vascular Endothelial Growth Factor (VEGF), Stromal cell-derived factor 1 (SDF-1α), and Stem Cell Factor (SCF). All measured from serum blood samples in units of pg/mL.

Markers of Neo-angiogenesis

时间窗: Baseline to Month 3, Baseline to Month 6

Markers of neo-angiogenesis reported as the percentage of Cluster of Differentiation 31 positive cells (CD31+), as measured from serum blood samples and expressed as a percentage.

Endothelial Progenitor Cell Colony Forming Units (EPC-CFUs)

时间窗: Baseline, Month 3, Month 6

Endothelial Progenitor Cell (EPC) Colony Forming Units (CFUs) as measured from peripheral blood samples in units of average cells per well.

次要结局

  • Penile Blood Flow(Baseline)
  • EDITS Questionnaire Scores(Month 3 and Month 6)
  • Incidence of Serious Adverse Events (SAEs)(Baseline, up to 6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Thomas Masterson

Assistant Professor

University of Miami

研究点 (1)

Loading locations...

相似试验